INmune Bio Reports Revenue Increase and Narrowed Net Loss in Q1 2025

INmune Bio, Inc. reported its financial results for the first quarter of 2025, revealing a revenue increase to $50,000 from $14,000 in the same period last year. The company’s operating expenses decreased to $9.96 million from $11.03 million, primarily due to reduced research and development costs associated with its Alzheimer’s clinical program. As a result, the net loss for the quarter narrowed to $9.74 million, compared to a loss of $11.03 million in the prior year, reflecting a positive shift in financial performance.

The company’s total assets as of March 31, 2025, were $37.80 million, down from $39.56 million at the end of 2024. Current assets also decreased to $20.96 million from $22.66 million, while total liabilities rose to $8.13 million from $7.47 million. The increase in liabilities was attributed to higher accounts payable and accrued liabilities. INmune Bio's stockholders' equity decreased to $29.67 million from $32.10 million, driven by the net loss and other comprehensive losses.

Strategically, INmune Bio has made significant advancements in its product development pipeline. The company is focused on three main platforms: DN-TNF for Alzheimer’s and treatment-resistant depression, CORDStrom for recessive dystrophic epidermolysis bullosa, and INKmune for cancer treatment. Notably, the company entered a license agreement with Great Ormond Street Hospital for exclusive access to clinical trial data related to CORDStrom, which is expected to facilitate regulatory submissions in the near future.

Operationally, INmune Bio's employee headcount has increased, reflecting its ongoing commitment to advancing its clinical programs. The company reported a weighted average of 22.5 million shares outstanding, up from 18 million a year earlier, indicating a potential increase in investor interest. The company also raised approximately $5.3 million through the sale of common stock during the quarter, which will support its ongoing research and development efforts.

Looking ahead, INmune Bio anticipates continued losses as it invests in the development of its product candidates. The company has expressed concerns about its liquidity, projecting that its current cash reserves may not sustain operations for the next year without additional financing. Management is exploring various funding strategies, including equity sales and collaborations, to secure the necessary capital for its ongoing projects. The company remains optimistic about the potential of its product candidates and their ability to address significant unmet medical needs.